Published in Biomed Res Int on August 25, 2013
Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells. PLoS One (2014) 1.07
Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line. PLoS One (2014) 0.82
Emerging and Evolving Ovarian Cancer Animal Models. Cancer Growth Metastasis (2015) 0.82
Culture models to define key mediators of cancer matrix remodeling. Front Oncol (2014) 0.81
High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. Acta Histochem Cytochem (2014) 0.81
Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog (2014) 0.76
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72
Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer (2004) 10.31
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell (2002) 9.61
The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer (2005) 8.99
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med (2011) 8.93
A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med (2011) 8.63
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer (2008) 7.86
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
Endometriosis. N Engl J Med (2009) 6.82
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A (2010) 6.54
Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol (2007) 5.68
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst (2000) 5.62
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol (2007) 5.12
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet (2006) 4.76
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2000) 4.48
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Ovarian cancer. Lancet (2009) 3.95
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77
A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol (2008) 3.59
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest (2010) 3.11
Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer (2010) 2.52
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer (2008) 2.47
Prophylactic oophorectomy in premenopausal women and long-term health. Menopause Int (2008) 2.26
International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst (2003) 2.14
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer (2010) 2.13
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol (2008) 2.09
Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer (2010) 1.88
Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch (2012) 1.80
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst (2003) 1.75
Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin (2011) 1.68
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer (2006) 1.67
A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol (2009) 1.67
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer (2006) 1.65
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61
A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. Gynecol Oncol (2010) 1.56
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am J Pathol (2010) 1.46
HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology (2005) 1.41
BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol (2003) 1.31
Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. Am J Surg Pathol (2010) 1.29
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer (2012) 1.24
Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol (2004) 1.22
Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res (2004) 1.21
Carcinoma of the ovary. J Epidemiol Biostat (2001) 1.09
PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer (2011) 1.08
The role of PARP1 in the DNA damage response and its application in tumor therapy. Front Med (2012) 1.06
Alterations in the p53 pathway and prognosis in advanced ovarian cancer: a multi-factorial analysis of the EORTC Gynaecological Cancer group (study 55865). Eur J Cancer (2006) 0.98
Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am J Surg Pathol (2009) 0.98
Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol (2005) 0.96
Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One (2013) 0.94
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol (2010) 0.91
Association of p21, p21 p27 and p21 p53 status to histological subtypes and prognosis in low-stage epithelial ovarian cancer. Cancer Genomics Proteomics (2013) 0.90
p21 and p53 in ovarian carcinoma: their combined staining is more valuable than either alone. Cancer (2001) 0.89
Role of cell-cycle regulatory proteins in gynecological cancer. J Cell Physiol (2003) 0.88
Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res (2010) 0.88
Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer (2011) 0.87
Ovarian epithelial dysplasia and prophylactic oophorectomy for genetic risk. Int J Gynecol Cancer (2009) 0.86
Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83
KRas-LCS6 polymorphism does not impact on outcomes in ovarian cancer. Am J Cancer Res (2012) 0.83
HER-dimerization inhibitors: evaluating pertuzumab in women's cancers. Expert Opin Biol Ther (2010) 0.82
Her-2/neu expression is a negative prognosticator in ovarian cancer cases that do not express the follicle stimulating hormone receptor (FSHR). J Ovarian Res (2013) 0.81
Cyclin-dependent kinase inhibitors CIP1 (p21) and KIP1 (p27) in ovarian cancer. J Cancer Res Clin Oncol (2005) 0.79
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res (2000) 3.95
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res (2001) 2.29
Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol (2009) 2.13
Informed versus randomised consent to clinical trials. Lancet (1995) 2.07
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res (2000) 1.82
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol (1996) 1.74
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res (1999) 1.66
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer (2005) 1.61
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res (1998) 1.54
Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol (2011) 1.42
Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst (1997) 1.41
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol (2009) 1.30
Selecting high-risk early breast cancer patients: what to add to the number of metastatic nodes? Eur J Cancer (1996) 1.26
Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev (2010) 1.19
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst (1996) 1.13
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol (2009) 1.10
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer. Br J Cancer (2006) 1.09
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res (2000) 1.02
Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer (1996) 0.99
Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study. Lancet (1988) 0.97
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol (2009) 0.95
Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort. Ann Oncol (2011) 0.94
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Res Treat (2012) 0.94
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study. Ann Oncol (2006) 0.91
Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis (2005) 0.91
Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer. Br J Cancer (1991) 0.91
Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol (2005) 0.89
Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol (1998) 0.88
Expression of proto-oncogene c-kit in high risk prostate cancer. Eur J Surg Oncol (2004) 0.87
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. Br J Cancer (2013) 0.87
Survival, quality of life and breast cancer. Ann Oncol (2001) 0.86
Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review. Int J Immunopathol Pharmacol (2006) 0.86
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. Ann Oncol (2002) 0.85
Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int J Immunopathol Pharmacol (2006) 0.85
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol (2009) 0.84
Second-line treatment for renal cell cancer. Br J Cancer (2012) 0.84
An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. Ann Oncol (2004) 0.84
Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients. Neurology (1996) 0.83
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. Cancer (2000) 0.83
Distress and family functioning in oncogenetic counselling for hereditary and familial breast and/or ovarian cancers. J Genet Couns (2007) 0.83
Prognosis of chronic myelomonocytic leukemia. Haematologica (1996) 0.83
A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients. Clin Cancer Res (1999) 0.81
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A. Int J Cancer (2000) 0.81
Reconstructing the genealogy of a BRCA1 founder mutation by phylogenetic analysis. Ann Hum Genet (2008) 0.81
KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. Br J Cancer (2012) 0.81
Meconial peritonitis in a rare association of partial ileal apple-peel atresia with small abdominal wall defect. Pediatr Med Chir (2014) 0.80
Management and treatment of triple-negative breast cancer patients from the NEMESI study: an Italian experience. Eur J Cancer (2011) 0.80
Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer. Int J Immunopathol Pharmacol (2008) 0.80
Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer. Eur J Cancer (1993) 0.80
A predictive index of axillary nodal involvement in operable breast cancer. Br J Cancer (1996) 0.80
[The request for consent in clinical research: a randomized study in healthy subjects]. Epidemiol Prev (1995) 0.80
Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer. Chemioterapia (1985) 0.80
First-line systemic therapy for metastatic breast cancer and management of pleural effusion. Ann Oncol (1995) 0.79
Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production. Clin Cancer Res (2000) 0.79
Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab. Cancer Chemother Pharmacol (2008) 0.78
A prospective randomized trial of doxorubicin versus idarubicin in the treatment of advanced breast cancer. Cancer (1989) 0.78
Pegylated liposomal doxorubicin in stage IVB mycosis fungoides. Br J Dermatol (2005) 0.78
Salvage chemotherapy with CCNU and methotrexate for small cell lung cancer resistant to CAV/PE alternating chemotherapy. Tumori (1991) 0.77
Hypothalamic-pituitary-ovarian axis in women with operable breast cancer treated with adjuvant CMF and tamoxifen. Tumori (1986) 0.77
Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. Clin Cancer Res (2001) 0.77
Focus on paediatric and adolescent varicocoele: a single institution experience. Int J Androl (2012) 0.77
Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs. Br J Cancer (2002) 0.77
Comment on 'Cancer genetic counselling' by P. Mandich et al. (Ann Oncol 2005; 16: 171). Ann Oncol (2005) 0.75
Re: Perabo FGE and Muller SC. New agents for treatment of advanced transitional cell carcinoma. Ann Oncol 2007; 18: 835-843. Ann Oncol (2007) 0.75
The adjuvant treatment of ovarian cancer: result of the pilot study of a new combination chemotherapeutic regimen (DAC). Eur J Gynaecol Oncol (1989) 0.75
Prognostic factors in human colorectal cancer. Tumori (1997) 0.75
Laparoscopic management of an isolated left fallopian tube torsion due to twisted Morgagni hydatid in a pre-menarcheal girl. Pediatr Med Chir (2014) 0.75
LH-RH analogue Zoladex in the treatment of pre- and perimenopausal women with metastatic breast cancer (results of the Italian Cooperative Study). Eur J Gynaecol Oncol (1991) 0.75
[Evaluation of quality of life in oncology. Rationale and objectives of the first phase of the Quality of Life in Oncology project]. Tumori (1997) 0.75
Epidermal inclusion cyst of the penis after urethroplasty causing an urethro-cutaneous fistula: a first case report. Pediatr Med Chir (2014) 0.75
[Association of gastric cancer and hepatitis. A theory to be verified]. Minerva Chir (1978) 0.75
The treatment of metastatic pleural effusion in breast cancer: report of 25 cases. Tumori (1987) 0.75
Insurance for independent cancer trials. Ann Oncol (2004) 0.75
Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR. J Endocrinol Invest (2005) 0.75
Ovarian metastasis following gallbladder carcinoma: a case report. Eur J Gynaecol Oncol (2010) 0.75
CA 15-3 in human breast cancer. Comparison with tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA). Int J Biol Markers (1991) 0.75
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer. Oncology (1999) 0.75
Letter to the Editor - miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R. Eur Rev Med Pharmacol Sci (2016) 0.75
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study. Am J Clin Oncol (1994) 0.75
Neuroendocrine differentiation after neoadjuvant hormonal treatment in prostate cancer. Minerva Urol Nefrol (2005) 0.75
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer. Tumori (1993) 0.75
Endocrine factors in the outcome of systemic adjuvant therapy of early breast cancer. Ann N Y Acad Sci (1993) 0.75
Prognostic significance of circulating immune complexes in a long-term follow-up of breast cancer patients. Oncology (1988) 0.75